Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹56 Cr
Revenue (TTM)
₹80 Cr
Net Profit (TTM)
₹5 Cr
ROE
11.1 %
ROCE
15.8 %
P/E Ratio
11.7
P/B Ratio
0.7
Industry P/E
26.59
EV/EBITDA
6.8
Div. Yield
0 %
Debt to Equity
0.3
Book Value
₹11.7
EPS
₹1.5
Face value
10
Shares outstanding
65,990,646
CFO
₹-7.53 Cr
EBITDA
₹27.41 Cr
Net Profit
₹14.28 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
JFL Life Sciences
| -28.3 | -18.6 | -31.1 | -48.7 | -6.6 | -- | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
JFL Life Sciences
| -59.2 | 123.6 | 22.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
JFL Life Sciences
|
8.6 | 56.4 | 80.1 | 4.8 | 10.5 | 11.8 | 11.7 | 0.7 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,499.2 | 9,167.3 | 1,196.4 | 149.4 | -- | 27.5 | 61.3 | 13.1 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable... alkaloids; Read more
Incorporated
2010
Chairman
Smiral Ashwinkumar Patel
Managing Director
Smiral Ashwinkumar Patel
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about JFL Life Sciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of JFL Life Sciences Ltd is ₹8.55 (NSE) as of 02-Apr-2026 IST. JFL Life Sciences Ltd has given a return of -6.62% in the last 3 years.
The P/E ratio of JFL Life Sciences Ltd is 11.70 times as on 02-Apr-2026, a 56 discount to its peers’ median range of 26.59 times.
The P/B ratio of JFL Life Sciences Ltd is 0.73 times as on 02-Apr-2026, a 84 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
13.84
|
1.39
|
|
2024
|
4.37
|
1.16
|
|
2023
|
4.31
|
1.07
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of JFL Life Sciences Ltd are Rs 21.19 and Rs 8.55 as of 03-Apr-2026.
JFL Life Sciences Ltd has a market capitalisation of ₹ 56 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in JFL Life Sciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.40
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.